• Umesh Nandkumar Khatavkar Formulation Research Division, Aurobindo Pharma Limited Research Centre, 313, Bachupally, Quthubullapur, Hyderabad 500072, India
  • K Jayaram Kumar
  • Shamkant Laxman Shimpi


The objective of this review is to study different novel approaches for achieving controlled release for oral administration. There is need of developing cost-effective generic products which will be comparable to the established innovator products with respect to in vivo performance. The innovator products being developed based on exhaustive research are developed utilizing novel platform technologies, have been protected with patents. These platform technologies require specialized manufacturing equipment’s and that additionally imparts overall cost to the drug product. This review also contains review on existing technologies utilized for controlling the drug release of actives and also focuses on authors work on the development of cost-effective novel approaches for developing controlled release of some selected central nervous system acting drugs viz galantamine hydrobromide (GAH) and paroxetine hydrochloride hemihydrate (PHH). The existing approved reference products of selected molecules are available based on extended release multi-particulate delivery system and Geomatrix based platform technology for GAH and PHH respectively. This review also explains authors work in developing different controlled release approaches for achieving similar in vivo performance comparable to the reference product. The use of high viscosity grade of hydroxypropyl cellulose (HPC) as a release controlling matrix former in order to control the release of GAH by direct compression into mini tablets offers a feasible dosage form which further can be filled into capsules. Hydroxypropylmethylcellulose (HPMC) based matrix tablets which were further coated using methacrylic acid copolymer were found to be a suitable method to formulate single layer controlled release PHH.

Keywords: Paroxetine hydrochloride hemihydrates, Galantamine hydrobromide, Aquacoat, Hydroxypropyl methylcellulose, Geomatrix technology, In vivo


1. Conte U, Maggi L, Colombo P, La MA. Multi-layered hydrophilic matrices as constant release devices (Geomatrix® systems). J Controlled Release 1993;26:39–47.
2. Conte U, Maggi L. Modulation of the dissolution profiles from Geomatrix multi-layer matrix tablets containing drugs of different solubility. Biomaterials 1996;17:889–6.
3. Rodriquez M, Vila-Jato JL, Torres D. Design of a new multi particulate system for potential site-specific and controlled drug delivery to the colonic region. J Controlled Release 1998;55:67-77.
4. Khan GM, Jiabi Z. Formulation and in vitro evaluation of Ibuprofen-Carbopol 974P-NF controlled release matrix tablets III: influence of co excipients on the release rate of the drug. J Controlled Release 1998;54:185-90.
5. Efentakis M, Koutlis A, Vlachou M. Development and evaluation of multiple oral unit and single unit hydrophilic controlled release systems. AAPS PharmSciTech 2000;4:1-9.
6. Verma RK, Garg S. Current status of drug delivery technologies and future directions. Pharm Technol 2011;25:1–4.
7. Krishnaiah YSR, Karthikeyan RS, Gourisankar V, Satyanarayana V. Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble Trimetazidine dihydrochloride. J Controlled Release 2002;81:45-56.
8. Tiwari SB, Murthy KT, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of Tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech 2003;4:1-6.
9. Rao VM, Engh K, Qiu Y. The design of pH-independent controlled release matrix tablets for acidic drugs. Int J Pharm 2003;252:81-6.
10. Royce A, Li S, Weaver M, Shah U. In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2-O-methyladenosine. J Controlled Release 2004;97:79-90.
11. Korhonen O, Kanerva H, Vidgren M, Urtti A, Ketolainen J. Evaluation of novel starch acetate diltiazem controlled release tablets in healthy human volunteers. J Controlled Release 2004;95:515-20.
12. Kim C. Controlled release from triple layer donut-shaped tablets with enteric polymers. AAPS PharmSciTech 2005;6:1-8.
13. Jamzad S, Fassihi R. Development of a controlled release low dose class II drug Glipizide. Int J Pharm 2005;312:24-32.
14. Lopes CM, Lobo JSM, Costa P. Directly compressed mini matrix tablets containing Ibuprofen: preparation and evaluation of sustained release. Drug Dev Ind Pharm 2006;32:95-106.
15. Siepmann F, Siepmann J, Walther M, MacRae RJ, Bodmeier R. Polymer blends for controlled release coatings. J Controlled Release 2007;125:1-15.
16. Ishida M, Abe K, Hashizume M, Kawamura M. A novel approach to sustained pseudoephedrine release: Differentially coated mini-tablets in HPMC capsules. Int J Pharm 2008;359:46-52.
17. Dey NS, Majumdar S, Rao MEB. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 2008;7:1067–75.
18. Baloglu E, Senyigit T. A design and evaluation of layered matrix tablet formulations of metoprolol tartrate. AAPS PharmSciTech 2010;11:563-73.
19. Aboelwafa AA, Basalious EB. Optimization and in vivo pharmacokinetic study of a novel controlled release Venlafaxine hydrochloride three-layered tablet. AAPS PharmSciTech 2010;11:1026-37.
20. Rao NGR, Hadi MA, Panchal HA. A novel approach to sustained Montelukast sodium release: Differentially coated mini-tablets in HPMC capsules. Int J Pharm Biomed Res 2011;2:90-7.
21. Mamani PL, Caro RR, Veiga MD. Matrix tablets: the effect of hydroxypropyl methylcellulose/anhydrous dibasic calcium phosphate ratio on the release rate of a water soluble drug through the gastrointestinal tract in vitro tests. AAPS PharmSciTech 2012;13:1073-83.
22. Mashkovsky MD, Kruglikova–Lvova RP. On the pharmacology of the new alkaloid galantamine. Farmakologia Toxicologia 1951;14:27–30.
23. Proskurnina NF, Yakovleva AP. Alkaloids of Galanthus woronowi. II Isolation of a new alkaloid. Zhurnal Obshchei Khimii 1952;22:1899–902.
24. Inventor Davis. The method of treating Alzheimer’s disease. US Patent No. 4663318; 1987.
25. Cronin JR. The plant alkaloid Galantamine: approved as a drug; sold as a supplement. Alternative Complementary Ther 2004;7:380-3.
26. Sean C Sweetman. Martindale: The complete drug reference. Chicago, IL: Pharmaceutical Press; 2005.
27. US Patent 7160559. Inventor Mc Gee, Controlled release Galantamine composition; 2007.
28. Kays LA, Sileno AP, Brandt GC, Foerder CA, Quay SC. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 2007;335:138-46.
29. Caro VD, Giandalia G, Siragusa MG, Campisi G, Giannola LI. Galantamine delivery on buccal mucosa: permeation enhancement and design of matrix tablets. J Bioequivalence Bioavailability 2009;1:127-34.
30. Jagadeesh TR, Chary RBR. Development of a novel oral multi-particulate drug delivery system of galantamine hydrobromide. J Pharm Res 2011;4:77-9.
31. Biswal B, Sharma D. Design, Development and evaluation of galantamine hydrobromide bilayer sustained release tablet. Pharm Lett 2013;5:12-9.
32. Woo FY, Basri M, Masoumi HRF, Ahmad MB, Ismail M. Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in a transdermal patch for Alzheimer’s disease. Int J Nanomed 2015;10:3879-86.
33. Ravi V, Kumar TMP, Rao NR. Investigation of kondagogu gum as a carrier to develop polymeric blend beads of galantamine hydrobromide. World J Pharm Pharm Sci 2015;4:1802-6.
34. Khatavkar UN, Shimpi SL, Kumar KJ, Deo KD. Controlled release reservoir mini tablets approach for controlling the drug release of galantamine hydrobromide. Pharm Dev Technol 2012;17:437–42.
35. Khatavkar UN, Shimpi SL, Kumar KJ, Deo KD. Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology. Pharm Dev Technol 2013;18:1148–58.
36. Sweetman SC. Martindale-the complete drug reference. 34th ed. London: Pharmaceutical Press; 2005.
37. WO 2007/035816. Assignee: Dr Reddy’s Laboratories) Paroxetine compositions; 2007.
38. Jin SJ, Yoo YH, Kim MS, Kim JS, Park JS, Hwang SJ. Paroxetine hydrochloride controlled release POLYOX matrix tablets: screening of formulation variables using Plackett-Burman screening design. Arch Pharm Res 2008;31:399–405.
39. Khatavkar UN, Shimpi SL, Kumar KJ, Deo KD. Development and comparative evaluation of in vitro, in vivo properties of novel controlled release compositions of paroxetine hydrochloride hemihydrate as against Geomatrix™ platform technology. Drug Dev Ind Pharm 2013;39:1175–86.
40. Vaidya N, N yak R, Benhar R, Narayanswamy VB. Design and evaluation of controlled release tablets of paroxetine hydrochloride. Int Res J Pharm 2013;4:84-62.
260 Views | 2550 Downloads
How to Cite
Review Article(s)